New drug combo targets rare lung cancer in early trial
NCT ID NCT07200947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this approach can shrink tumors or delay cancer growth. About 28 adults with this specific cancer type will take part. The study is not yet open for enrollment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pfizer drug takes on Hard-to-Treat cancers
- New pill hopes to shrink lung tumors in early trial
- Promising combo targets rare lung cancer in new trial
- New targeted therapy aims to outshine standard chemo for HER2-mutant lung cancer
- New drug cocktail aims to shrink lung tumors
- New drug cocktail hopes to tackle tough lung cancer